|
| | Edaravone iMpurity P3 Basic information |
| Product Name: | Edaravone iMpurity P3 | | Synonyms: | Edaravone iMpurity P3;4,5-dihydro-a,a,3-triMethyl-5-oxo-1-phenyl- 1H-Pyrazole-4-Methanesulfonic acid;2-(3-Methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)propane-2-sulfonic acid;4,5-Dihydro-alpha,alpha,3-trimethyl-5-oxo-1-phenyl-1H-pyrazole-4-methanesulfonic acid;Edaravone P3 Impurity;2-(5-hydroxy-3-methyl-1-phenyl-1Hpyrazol-4-yl)propane-2-sulfonic acid;Edaravone P3;Edaravone Impurity 3 Sodium Salt | | CAS: | 1323485-71-7 | | MF: | C13H16N2O4S | | MW: | 296.34 | | EINECS: | | | Product Categories: | | | Mol File: | 1323485-71-7.mol |  |
| | Edaravone iMpurity P3 Chemical Properties |
| density | 1.35±0.1 g/cm3 (20 ºC 760 Torr) | | pka | 0.73±0.50(Predicted) |
| | Edaravone iMpurity P3 Usage And Synthesis |
| Uses | 2-?(3-?Methyl-?5-?oxo-?1-?phenyl-?4,?5-?dihydro-?1h-?pyrazol-?4-?yl)?propane-?2-?sulfonic Acid is an impurity of Edaravone (E335000) which inhibits the disease activity in rheumatoid arthritis. Edaravone can significantly enhance IR flap viability and protect flap vessels, which is related to scavenging oxygen free radicals, reducing the consumption of SOD, reducing the extent of lipid peroxidation and inflammation, and protecting functional structure of vessels in the early stages of reperfusion. |
| | Edaravone iMpurity P3 Preparation Products And Raw materials |
|
